18191 Experience of using rituximab and corticosteroid combination therapy for bullous pemphigoid: A 9-year case series analysis

Abstract

Background: Bullous pemphigoid is the most common autoimmune bullous disease, with a mortality rate up to 13∼38% due to increased susceptibility in the aging population, high prevalence of comorbidities, and the use of immunosuppressants. In the recent years, a few case series, including one precedent case series from our facility, have demonstrated an increased rate of complete remission, steroid-sparing effect and a favorable safety profile of rituximab as a treatment for bullous pemphigoid.